Jintiange combined with alfacalcidol improves muscle strength and balance in primary osteoporosis: A randomized, double-blind, double-dummy, positive-controlled, multicenter clinical trial

Hanting Liang a,1, Ou Wang a,1, Zhifeng Cheng b, Peijin Xia c, Liang Wang d, Jie Shen e, Xijian Kong f, Yuhong Zeng g, Aijun Chao h, Limei Yan i, Hua Lin j, Haibiao Sun k, Qun Cheng l, Mei Zhu m, Zhenming Hun n, Zhenlin Zhang o, Hai Tang p, Weibo Xia q

a Key Laboratory of Endocrinology of National Health Commission, Department of Endocrinology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, 100730, China
b Department of Endocrinology, The Fourth Affiliated Hospital of Harbin Medical University, China
c Department of Endocrinology, The Central Hospital of Fuling District, China
d Department of Geriatric Medicine, The Eighth Medical Center of Chinese PLA General Hospital, China
e Department of Endocrinology and Metabolism, The Third Affiliated Hospital of Southern Medical University, China
f Osteoporosis Medical Center, Luoyang Orthopedic-Traumatological Hospital of Henan Province (Henan Provincial Orthopedic Hospital), China
g Department of Osteoporosis, Honghui Hospital of Xi’an Jiaotong University Medical School, China
h Department of Osteoporosis, Tianjin Hospital of Tianjin City, China
i Department of Osteoporosis, Tianjin Hospital of Tianjin Clay, China
j Department of Endocrinology, Changchun Central Hospital, China
k Department of Osteoporosis, Affiliated Hospital of Southern Medical University, China
l Department of Osteoporosis, Affiliated Hospital of Shantou Medical University, China
m Department of Orthopedic, The First Hospital of Shantou Medical University, China
n Department of Osteoporosis, Affiliated Hospital to Fudan University, China
o Department of Endocrinology and Metabolism, Tianjin Medical University General Hospital, China
p Department of Orthopedic, The First Affiliated Hospital of Chongqing Medical University, China
q Department of Osteoporosis and Bone Diseases, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University, China
r Department of Orthopedic, Beijing Friendship Hospital, Capital Medical University, China

ARTICLE INFO

Keywords:
Jintiange capsule
Artificial tiger bone powder
Osteoporosis
Muscle strength
Balance
Fall risk

ABSTRACT

Objective: To investigate the effectiveness of a Chinese patent medicine, Jintiange capsules with the main component of artificial tiger bone powder, combined with alfacalcidol on muscle strength and balance of the lower extremities in patients with primary osteoporosis.

Design: A randomized, double-blind, double-dummy, positive-controlled, multicenter clinical trial.

Subjects and methods: A total of 400 patients diagnosed with primary osteoporosis or osteopenia were recruited and randomized into the Jintiange or control groups. During the 52-week treatment, the participants in the Jintiange group were treated with Jintiange capsules (1.2 g each time, 3 times per day) and calcium carbonate, while those in the control group were treated with calcium carbonate (element calcium 0.3 g, twice a day). In the per-protocol set. Comparing the data at week 52 from those at baseline, the TUG time decreased from 9.60 ± 2.25 s to 8.53 ± 2.06 s (p < 0.001) in the Jintiange group and decreased from 9.50 ± 1.91 s to 9.11 ± 1.95 s (p < 0.001) in the control group; the CRT time decreased from 11.49 ± 4.05 s to 8.57 ± 2.13 s (p < 0.001) and 11.17 ± 3.21 s to 9.74 ± 1.98 s (p < 0.001) in the Jintiange and control groups, respectively; the number of correct steps in the TGT increased significantly in both the control (7.40 ± 1.27 vs. 7.69 ± 0.87, p < 0.01) and Jintiange groups (7.21 ± 1.58 vs. 7.60 ± 1.12, p < 0.001). At the end of the study, the TUG and CRT
results in the Jintiange group were superior to those in the control group (all p value < 0.05), while no obvious difference was found in the TGT between the two groups. At week 52, the high fall risk proportions in the Jintiange group were significantly lower than those in the control group according to TUG (3.25% vs. 9.55%, p = 0.023) and CRT (20.78% vs. 33.76%, p = 0.01).

Conclusion: Jintiange capsules combined with alfacalcidol can effectively improve muscle strength and the balance of the lower extremities and reduce fall risk in patients with primary osteoporosis/osteopenia. This is the post hoc analysis of a randomized clinical trial (ChiCTR-IPR-16008533). The subjects came from a randomized, double-blind, double-dummy clinical trial conducted in 16 centers in mainland China to evaluate the effectiveness and safety of Jintiange capsules in patients with primary osteoporosis, of which the primary and secondary outcomes, including BMD and bone turnover markers (BTMs), as well as safety data, have been published [19]. In brief, from November 2016 to May 2019, 400 patients diagnosed with primary osteoporosis or osteopenia with risk factors were enrolled. Inclusion criteria included (1) age <80 years and being male >50 years or female >45 years and not having a menstrual period for at least 1 year or > 60 years for those whose menopausal age is unclear; (2) a T-score of BMD evaluated by dual-emission X-ray absorptiometry (DXA) ≤ -2.5 standard deviation (SD) at lumbar spine L1–4 (L1–4) or FN or TH, a T-score between −2.5 SD and −1.0 SD, combined with one or more risk factors (evaluated by the International Osteoporosis Foundation questionnaire) or an Osteoporosis Self-assessment Tool for Asians (OSTA) score ≤ -1; and (3) a body mass index (BMI) between 18.5 and 28.0 kg/m². Exclusion criteria included (1) secondary osteoporosis, including primary hyperparathyroidism, rheumatoid arthritis, multiple myeloma, etc. or patients with hyperphosphatemia, bone tuberculosis and malignant bone tumor; (2) patients with severe concurrent diseases, including poorly controlled hypertension or diabetes, hepatic dysfunction (ALT or AST >1.5-fold of upper limit), or renal insufficiency (eGFR<60 ml/min); and (3) taking medicines that affect vitamin D metabolism in the past 3 months, drugs affecting bone metabolism in the past 6–12 months (estrogen, selective estrogen receptor modular, calcitonin, fluoride, synthetic steroids and parathyroid hormone in the past 6 months, or bisphosphonates in the past 12 months), and any other drug or treatment that researchers believe may interfere with this trial. The trial was performed with the approval of Peking Union Medical Hospital Ethics Committee (HS-1047) and in accordance with Declaration of Helsinki and good clinical practice (GCP) guidelines. Written informed consent was obtained from all the participants.

2. Study design and treatment

This is the post hoc analysis of the abovementioned clinical trial on Jintiange treatment in Chinese osteoporotic patients, where the sample size was calculated according to the primary outcomes of BMD changes as previously described [19]. A total of 400 participants were divided into Jintiange and control groups equally by the stratified block randomization method. The participants in the Jintiange group were treated with Jintiange capsules (0.4 g per capsule, containing 65 mg amino acids, 55 mg elemental calcium, and 35 mg phosphorus, 1,2 g, tid)
and calcium carbonate simulant (1 tablet, bid). The participants in the control group were treated with calcium carbonate tablets (elemental calcium 0.3 g, bid) and a Jintiange capsule simulant (3 capsules, tid). Alfacalcidol (0.25 μg, Qd) was applied in both groups. The course of treatment was 52 weeks for both groups. The participants were visited on day –14–0, day 0, week 4 ± 3 days, week 12 ± 5 days, week 24 ± 5 days, week 36 ± 5 days and week 52 ± 5 days. Serum levels of total 25-hydroxy vitamin D (25OHD) and other biochemical parameters were measured at each visit, while BMD of L1-L4, FN and TH were measured by DXA at baseline, week 24 and week 52, respectively, as previously reported [19].

2.3. Sample size calculation

The sample size was calculated according to BMD changes as the primary outcome for the superiority design. The calculation of the therapeutic efficacy in the aspect of BMD improvement is based on the standards from the “National Medical Products Administration” [20]. It was estimated that the improvements in BMD in the Jintiange group and the control group were 0.06 g/cm² and 0.03 g/cm², respectively, and the SD of BMD in the two groups was 0.1 g/cm². Based on 80% power and a one-sided 2.5% level of significance, the mean BMD in the Jintiange group was greater than that in the control group, the SDs of BMD in the two groups were equal, and R = 1. Considering a drop-out rate of 20%, the minimum sample size was 400 participants for the double-blind study, including 200 participants in the Jintiange group and 200 participants in the control group.

2.4. Evaluation of muscle strength and balance of the lower extremities

The functional ability and balance of patients were evaluated by three functional assessment tests. The timed up and go test (TUG) was used to evaluate the functional mobility, muscle function, gait speed and balance of the participants. The procedure of the TUG test involves the participant standing from a standard arm chair with an approximate seat height of 48 cm and an approximate armrest height of 68 cm, walking a distance of 3 m, turning, walking back and sitting down again [21,22]. In the TUG test, individuals who need more than 12 s to complete the test are assessed as having a high risk of falls; otherwise, they are assessed as having a low risk of falls.

The main purpose of the chair rising test (CRT) is to evaluate hip muscle strength [23]. The participant is asked to rise from a chair with an approximate seat height of 48 cm and then sit down, repeating the process five times. A CRT test time ≤10 s indicates a low risk of falls. If the participant cannot complete the process of standing up and sitting down for five times or takes more than 10 s to do so, then were assessed as having a high risk of falls.

The tandem gait test (TGT) is mainly used to evaluate the balance of the lower extremities [23]. The participant starts walking 8 steps in a straight line on a special ruler (approximately 10 cm wide and 3 m long), one foot is placed in front of the other, and the distance between the two feet should be less than 1 cm, which can be recorded as a correct or successful step. If the foot deviates from the straight line more than the width of the foot, then the step is recorded as incorrect. This test was repeated three times, and the best result was taken as the final result. The TGT result is expressed as the number of successful steps. A result of less than 8 successful steps shows poor balance ability and a high risk of falls, while taking 8 successful steps was assessed as indicating a low risk of falls.

2.5. Falls and fractures

During the follow-up, incidents of nonvertical fractures and falls were self-reported by the participants. Spine X-rays were conducted at baseline and the 52nd week to evaluate new vertebral fractures. The formulas for the fall incident rate and the fracture incident rate are as follows:

fall incident rate = (the number of falls / total number of participants) × 100%
fracture incident rate = (the number of new fractures / total number of participants) × 100%

2.6. Dataset for analysis

According to the principle of intention-to-treat, the full analysis set (FAS) included all randomized participants taking our study drugs at least once. For those not completing the entire study process, the latest data were included in the analysis. General characteristics at baseline were analyzed in the FAS. The per-protocol population set (PPS) comprised participants who agreed with the study protocol, exhibited good compliance, did not take prohibited drugs during the study period, and completed a case report form. Efficacy data, including the TUG and CRT times and the number of correct steps in TGT, were analyzed in both the FAS and PPS.

2.7. Statistical analysis

All data were analyzed by SAS version 9.4. Normally distributed data are described as the mean ± SD, and abnormally distributed data are depicted as the median (Q1, Q3). Comparisons between groups were made with appropriate methods according to the type of data. Classified data at baseline and posttreatment were compared by the chi-square test or Fisher’s exact test, including sex, diagnosis and new fractures. Data on baseline information were tested by a two-sided test. Repeated measures ANOVA was used to compare repeated measures at different visits, including BMD, the TUG and CRT times, the number of correct steps in TGT, and their changes at each visit were compared to baseline. Repeated measures are depicted as the estimated value ± standard error. Both in the Jintiange group and the control group, McNemar’s test was used to analyze the change in the proportion of high fall risk at each visit compared with that at baseline. The incidences of new fracture and falls were tested by the chi-square test or Fisher’s exact test. Bivariate analysis was performed in the PPS to evaluate the relationship between BMDs and the TUG/CRT/TGT results, as well as changes in BMDs and changes in the TUG/CRT/TGT results from baseline to week 52. Multiple regression analysis was performed, where the results of the TUG/CRT/TGT and their changes after treatment were the dependent variables, and the independent factors included age, sex, fracture history, new fracture, new fall, and serum 25OHD level at baseline. Statistically significant differences were considered when the p value ≤ 0.05.

3. Results

3.1. General characteristics of all subjects and BMD at baseline and week 52 in the PPS

A total of 199 patients in the Jintiange group and 200 patients in the control group received randomization and at least one dose of medicine and entered the FAS analysis. There were 166 participants in the Jintiange group and 168 participants in the control group at the 52-week follow-up, among which 154 participants in the Jintiange group and 157 participants in the control group were included in the PPS (Fig. 1). General characteristics are listed in Table 1. Except for height (median of 158.0 cm in the Jintiange group vs. 157.0 cm in the control group, p = 0.048), there were no statistically significant differences in the general characteristics between the two groups. Additionally, there were no significant differences in BMD at baseline or week 52 in L1-L4, the FN, or the TH between the control and Jintiange groups (Table 2), as previously reported [19].
There were no significant differences in all of the indexes between the two groups at baseline.

Although compared with the data at baseline, the CRT times declined from week 4 in both groups (all $p$ values $<0.001$). The TUG time decreased significantly after week 4 in the Jintiange group, while it decreased significantly after week 24 in the control group (Table 3 and Fig. 2A).

The number of correct steps in the TGT and the change from baseline to each visit showed no significant differences between the Jintiange and control groups (Table 2), except for the number of correct steps at week 4 (7.58 ± 0.10 vs. 7.26 ± 0.10, $p = 0.026$). Compared to baseline, the

### Table 1

| Characteristics             | Control group (n = 200) | Jintiange group (n = 199) | $p$ value |
|-----------------------------|------------------------|---------------------------|-----------|
| Age (years old)             | 62.88 ± 7.42           | 63.11 ± 7.02              | 0.555     |
| Gender n (%)                | 60 (30.00%)            | 53 (26.63%)               | 0.455     |
| Height (cm)                 | 158.00 (155.00, 162.00)| 157.00 (153.00, 161.00)  | 0.048     |
| Weight (kg)                 | 60.00 (54.00, 65.00)   | 58.00 (52.50, 64.00)      | 0.161     |
| Systolic pressure (mmHg)    | 124.00 (117.00, 135.00)| 122.00 (116.00, 132.00)  | 0.235     |
| Diastolic pressure (mmHg)   | 75.00 (70.00, 80.00)   | 75.00 (70.00, 80.00)      | 0.637     |
| Serum T25OHD (ng/ml)        | 17.69 (13.03, 24.23)   | 17.68 (12.56, 24.21)      | 0.953     |
| L1-L4 (g/cm²)               | 0.84 (0.75, 0.93)      | 0.84 (0.75, 0.92)         | 0.875     |
| Femoral neck (g/cm²)        | 0.70 (0.62, 0.77)      | 0.67 (0.62, 0.76)         | 0.344     |
| Total hip (g/cm²)           | 0.80 (0.71, 0.86)      | 0.78 (0.70, 0.84)         | 0.179     |
| Diagnosis n (%)             | 111 (55.50%)           | 116 (58.29%)              | 0.573     |
| Osteopenia                  | 89 (44.50%)            | 83 (41.71%)               |           |

The normal distribution data is described as mean ± standard deviation, and the abnormal distribution data is depicted as median (interquartile: Q1, Q3). Abbreviations: FAS, full analysis set; BMI, body mass index; T25OHD, total 25-hydroxy vitamin D; BMD, bone mineral density.

### Table 2

| BMD in different positions | Time point | Control group | Jintiange group | $p$ value |
|---------------------------|------------|---------------|-----------------|-----------|
| L1-L4 (g/cm²)             | Baseline   | 0.851 ± 0.051 | 0.851 ± 0.052   | 0.961     |
|                           | W52        | 0.866 ± 0.051 | 0.859 ± 0.052   | 0.667     |
| Femoral neck (g/cm²)      | Baseline   | 0.695 ± 0.009 | 0.692 ± 0.009   | 0.820     |
|                           | W52        | 0.702 ± 0.009 | 0.696 ± 0.009   | 0.605     |
| Total hip (g/cm²)         | Baseline   | 0.791 ± 0.010 | 0.779 ± 0.010   | 0.355     |
|                           | W52        | 0.792 ± 0.010 | 0.774 ± 0.010   | 0.209     |

The data of BMD is depicted as estimated value ± standard error (SE). "**", "***", and "#" stand for $p < 0.05$, $p < 0.01$, and $p < 0.001$ between data at baseline and at week 52 within each group, respectively. Abbreviations: PPS, per-protocol set; BMD, bone mineral density.

TUG time was significantly shorter in the patients in the Jintiange group than in those in the control group (8.53 ± 0.16 s vs. 9.11 ± 0.16 s, $p = 0.012$), with the values decreasing by 1.07 ± 0.16 s ($-8.77 ± 1.59%$) and 0.39 ± 0.16 s ($-2.91 ± 1.57%$) in the Jintiange and control groups, respectively, compared with baseline ($p < 0.001$). The TUG time decreased significantly after week 4 in the Jintiange group, while it decreased significantly after week 24 in the control group (Table 3 and Fig. 2A).

Although compared with the data at baseline, the CRT times declined from week 4 in both groups (all $p$ values $<0.05$, Fig. 2B), the CRT time at week 52 was significantly shorter in the Jintiange group than that in the control group (8.57 ± 0.17 s vs. 9.14 ± 0.17 s, $p < 0.001$), and it decreased by $-2.90 ± 0.23$ s ($-21.93 ± 1.51%$) and $-1.43 ± 0.22$ s ($-8.99 ± 1.48%$) in the Jintiange and control groups, respectively. Since week 24, the decrease in CRT time was more obvious in the Jintiange group than in the control group (Table 3 and Fig. 2B).

The number of correct steps in the TGT and the change from baseline to each visit showed no significant differences between the Jintiange and control groups (Table 2), except for the number of correct steps at week 4 (7.58 ± 0.10 vs. 7.26 ± 0.10, $p = 0.026$). Compared to baseline, the
3.3. Comparison of fall risk before and after treatment

As shown in Fig. 3 and Table 4, the proportions of high fall risk evaluated by the TUG, CRT, and TGT in the two groups decreased with a similar trend. At baseline, the proportions of high fall risk according to the TUG, CRT, and TGT were comparable between the two groups. At the last visit, the percentages of high fall risk according to the TUG, CRT, and TGT were significantly lower in the Jintiange group than those in the control group according to the TUG, CRT, and TGT for the two groups. Blue and orange solid squares and orange solid circles represent the control and Jintiange groups, respectively. #: significant difference between the control and Jintiange groups, respectively. **: p < 0.01 and ***: p < 0.001, respectively, when data of posttreatment data compared with baseline data within each group. Blue and orange icons correspond to significant differences in the control and Jintiange groups, respectively.

Table 3

|                  | Baseline | W4     | W12    | W24    | W36    | W52    |
|------------------|----------|--------|--------|--------|--------|--------|
| **TUG**          |          |        |        |        |        |        |
| Control (sec)    | 9.50 ± 0.17 | 9.42 ± 0.18 | 9.32 ± 0.16 | 9.22 ± 0.14* | 9.10 ± 0.14** | 9.11 ± 0.16* |
| Jintiange (sec)  | 9.60 ± 0.17 | 9.29 ± 0.18* | 9.13 ± 0.16** | 8.96 ± 0.14*** | 8.66 ± 0.14*** | 8.53 ± 0.16*** |
| p1               | 0.654    | 0.604  | 0.388  | 0.181  | 0.024  | 0.012  |
| Control (%)      | +0.69 ± 1.69 | -0.28 ± 1.56 | -1.23 ± 1.31 | -1.64 ± 1.32 | -2.61 ± 1.41 | -2.91 ± 1.57 |
| Jintiange (%)    | -1.50 ± 1.71 | -2.72 ± 1.58 | -4.64 ± 1.32 | -7.57 ± 1.42 | -8.77 ± 1.59 |        |
| p2               | 0.362    | 0.272  |        | 0.068  | 0.013  | 0.009  |
| **CRT**          |          |        |        |        |        |        |
| Control (sec)    | 11.17 ± 0.29 | 10.68 ± 0.23* | 10.57 ± 0.27* | 10.26 ± 0.20*** | 10.01 ± 0.20*** | 9.74 ± 0.16*** |
| Jintiange (sec)  | 11.47 ± 0.29 | 10.73 ± 0.23** | 10.34 ± 0.27** | 9.63 ± 0.21*** | 9.19 ± 0.21*** | 8.57 ± 0.17*** |
| p3               | 0.466    | 0.873  | 0.549  | 0.030  | 0.005  | <0.001 |
| Control (%)      | -2.22 ± 1.48 | -2.99 ± 2.08 | -5.39 ± 1.55 | -7.29 ± 1.84 | -8.99 ± 1.48 |        |
| Jintiange (%)    | -3.24 ± 1.52 | -6.15 ± 2.14 | -12.05 ± 1.58 | -15.78 ± 1.89 | -21.93 ± 1.51 |        |
| p4               | 0.632    | 0.290  |        | 0.003  | 0.001  | <0.001 |
| **TGT**          |          |        |        |        |        |        |
| Control (correct steps) | 7.40 ± 0.11 | 7.58 ± 0.10* | 7.56 ± 0.09 | 7.75 ± 0.07*** | 7.79 ± 0.07*** | 7.69 ± 0.08** |
| Jintiange (correct steps) | 7.21 ± 0.12 | 7.26 ± 0.10 | 7.60 ± 0.09*** | 7.60 ± 0.07*** | 7.62 ± 0.07*** | 7.60 ± 0.08*** |
| p5               | 0.251    | 0.026  | 0.759  | 0.112  | 0.083  | 0.427  |
| Control (%)      | +4.67 ± 1.87 | +5.76 ± 4.07 | +10.58 ± 4.40 | +10.90 ± 4.60 | +9.56 ± 4.35 |        |
| Jintiange (%)    | +4.17 ± 1.90 | +14.08 ± 4.12 | +14.74 ± 4.45 | +16.45 ± 4.66 | +15.34 ± 4.41 |        |
| p6               | 0.850    | 0.152  | 0.506  | 0.397  | 0.351  |        |

Data was depicted as estimated value ± standard error (SE). Icons of “*”, “**” and “***” stand for p < 0.05, p < 0.01 and p < 0.001, respectively, when data of posttreatment data compared with baseline data within each group. Blue and orange icons correspond to significant differences in the control and Jintiange groups, respectively.

Fig. 2. Results of muscle strength and balance according to the TUG, CRT, and TGT evaluations for the two groups (PPS). (A) TUG times of the control and Jintiange groups. (B) CRT times of the two groups. (C) The number of correct steps in the TGT for the two groups. Blue solid squares and orange solid circles represent the control and Jintiange groups, respectively. All data are depicted as the estimated value ± standard error. “*”, “**” and “***” represent p < 0.05, p < 0.01 and p < 0.001, respectively, for posttreatment data compared with baseline data within each group. Blue and orange icons correspond to significant differences between the control and Jintiange groups, respectively.

Fig. 3. Proportions of high fall risk according to the TUG, CRT, and TGT evaluations for the two groups (PPS). (A) Proportion of high fall risk according to the TUG. (B) Proportion of high fall risk according to the CRT. (C) Proportion of high fall risk according to the TGT. Blue solid squares and orange solid circles represent the control and Jintiange groups, respectively. “*”, “**” and “***” represent p < 0.05, p < 0.01 and p < 0.001, respectively, for posttreatment data compared with baseline data within each group. Blue and orange icons correspond to significant differences in the control and Jintiange groups, respectively. #: significant difference between the control test groups at each visit, p < 0.05. Abbreviations: PPS, per-protocol set; W, week; TUG, timed up and go test; CRT, chair rising test; TGT, tandem gait test.

number of correct steps at week 52 increased significantly in both the control (7.40 ± 0.11 vs. 7.69 ± 0.08, p < 0.01) and Jintiange groups (7.21 ± 0.12 vs. 7.60 ± 0.08, p < 0.001), with increases of 9.56 ± 4.35% in the control group and 15.34 ± 4.41% in the Jintiange group (Table 3 and Fig. 2C).
to the TUG and TGT. From baseline to week 52, the high fall risk proportions in the Jintiange group decreased to the lowest according to the TUG (10.19% vs. 9.55%, p = 0.019), and the proportions also decreased from 29.87% to 19.48% according to the TGT (p < 0.05). In the control group, the high fall risk proportions decreased significantly at week 52 according to the TUG (55.84% vs. 33.76%, p = 0.001) and TGT (25.48% vs. 15.29%, p < 0.01), while there was no significant change according to the TUG (10.19% vs. 9.55%, p = 0.819).

3.4. Falls and new fractures

The falls and new fractures during the entire study were analyzed in the FAS dataset. In the Jintiange group, 17 participants (8.81%) had 1.5 ± 0.9 falls, and 18 participants (9.47%) had 1.2 ± 0.4 falls in the control group. There were two cases of new fractures (1.04%) in the control group and two cases (1.05%) in the Jintiange group. No significant differences were found for the percentages of either falls or new fractures between the two groups.

3.5. The relationships between TUG/CRT/TGT and BMD

As the bivariate analysis showed (Supplementary Table 1), there were no significant correlations between BMDs at different sites or the results of the three tests for the evaluation of muscle strength at baseline, except for a weak but significant correlation between TH BMD and TUG time (r = –0.174, p = 0.035) and the number of correct steps in the TGT (r = 0.168, p = 0.041) in the control group and a positive correlation between BMD at L1-L4 and TUG time (r = 0.168, p = 0.037) in the Jintiange group. Similar results were found at week 52, where only BMD at L1-L4 weakly correlated with CRT time (r = 0.219, p = 0.060), and the correct steps positively correlated with BMD at the FN (r = 0.160, p = 0.046) and TH (r = 0.222, p = 0.007) in the control group. In addition, there were no relationships between the BMD changes and the changes in the TUG, CRT, or TGT from baseline to week 52 in the two groups.

3.6. Factors influencing muscle strength evaluated by the TUG, CRT, and TGT

As multiple regression analysis showed (Supplementary Table 2), under most circumstances, age was associated with the TUG/CRT/TGT results (absolute values of β = 0.037–0.142, all p values < 0.01). Fracture history was associated with the TUG time in the Jintiange group at week 52 (β = –1.019, p = 0.007) and the CRT time in the control group at baseline (β = –1.341, p = 0.014). New falls had a significantly negative association with the number of correct steps in the TGT in the Jintiange group at baseline (β = –7.799, p < 0.001) and week 52 (β = –8.188, p < 0.001). The T25OHd level at baseline was positively associated with the number of correct steps in the TGT in the control group at baseline (β = 0.014, p = 0.041). Regarding the changes in the TUG, CRT, and TGT from baseline to week 52, the change in CRT time was positively associated with the TUG (p = 0.021), and the change in the number of correct steps in TGT was negatively associated with the T25OHd level at baseline (β = –0.013, p = 0.041) in the control group, but there were no associations between these changes and the independent variables in the Jintiange group.

4. Discussion

Sarcopenia and falls are the main causes of osteoporotic fractures; thus, fall prevention helps reduce the risk of fractures [24–26]. Currently, the pharmacies that can effectively treat sarcopenia and improve balance and muscle strength are very limited. This clinical trial first demonstrates that artificial tiger bone powder, a CPM, combined with alfacalcidol can effectively improve muscle strength and balance as evaluated by the TUG, CRT and TGT in patients with primary osteoporosis/osteopenia and is superior to calcium combined with alfacalcidol. Artificial tiger bone powder may be a new adjuvant drug to treat sarcopenia and ameliorate losses of muscle strength and balance.

At present, vitamin D agents are one of the main drugs considered for preventing falls, improving muscle strength/balance and treating sarcopenia. The results of a meta-analysis suggest that vitamin D supplementation has a mild but significantly positive effect on global muscle strength [27]. However, the effect of vitamin D on muscle strength and balance in patients with osteoporosis remains controversial due to the high heterogeneity in terms of participants’ characteristics and different assessments of muscle strength and balance across studies [28]. A meta-analysis indicates that vitamin D supplementation can decrease only 5% of falls in older women overall (risk ratio, RR = 0.948, p = 0.004); however, compared with vitamin D combined with calcium, vitamin D alone cannot reduce fall incidence (RR = 0.994, p = 0.73) or fracture rates (RR = 0.994, p = 0.37) [29]. Suzuki et al. reported that eldecalcitol alone can improve postural balance in older women with osteoporosis [30], while other studies indicated that eldecalcitol plus a bisphosphonate can improve the muscle strength of the back extensor and iliopoas, dynamic sitting balance, and the TUG and CRT results of postmenopausal osteoporotic women compared with bisphosphonate only [31,32]. Alfacalcidol can increase muscle power, muscle function and balance in patients with osteoporosis or osteopenia [33]. For other anti-osteoporotic drugs, only denosumab has been recently reported to significantly improve appendicular lean mass and handgrip strength in postmenopausal women with osteoporosis after a mean treatment duration of 3 years [34].

In this study, muscle strength and balance of the lower extremities were significantly improved in both groups, which further confirms the positive effect of alfacalcidol on muscle strength and balance in osteoporosis patients. However, the improvement in the Jintiange group was more obvious than that of in the control group with calcium, suggesting
that Jintiange also has a certain effect on ameliorating muscle strength and balance in patients with osteoporosis/osteopenia. There are two potential mechanisms by which Jintiange improves muscle strength and balance in osteoporosis patients. On the one hand, artificial tiger bone powder has been observed to significantly increase the wet weight of the gastrocnemius muscle of ovariecromized rats after 12 weeks of treatment and suppress osteoclasts by downregulating the osteoprotegerin (OPG)/receptor activator for nuclear factor κB and its ligand (RANKL/RANK) signaling pathway [16]. Recently, in mice overexpressing RANKL, Bonnet et al. found that a RANKL inhibitor restored muscle function by increasing muscle volume, muscle force and the temperature of the limb by reducing the expression of anti-myogenic and inflammatory genes (myostatin and protein tyrosine phosphatase receptor-γ) in the muscle [34]. Therefore, it is hypothesized that the inhibition of the OPG/RANKL/RANK signaling pathway may be the mechanism by which Jintiange improves muscle strength and function. On the other hand, artificial tiger bone powder has anti-inflammation and pain relief functions [15]. Previous studies have shown that Jintiange can significantly decrease pain scores (visual analog score) of those with primary osteoporosis with or without vertebral compression fractures [35–37]. Similar to the results of these studies, our clinical trial also found that the pain score decreased after week 4 in the two groups, and the pain score in the Jintiange group was significantly lower than that in the control group after week 36 [19]. It is concluded that with pain relief, patients may be more willing to exercise, and proper physical exercise has been proven beneficial for muscle strength and balance in osteoporosis patients [11, 38,39]. Further studies should be performed to confirm the mechanism by which Jintiange improves muscle strength and balance in osteoporosis patients.

Previous studies have shown that these three functional assessments for muscle strength and balance (the TUG, CRT and TGT) were useful evaluations of the risk of falls [22,23,33]. This study demonstrated that the percentage of high fall risk patients decreased in both groups after treatment, especially in the Jintiange group. However, there were no significant differences in the actual new falls or fractures between the two groups in our study, possibly due to the limited sample size and time of follow-up leading to the low number of events. Although only approximately 5% of all falls cause fractures, more than 90% of hip fractures result from falls [40,41]. Falls and fractures are inseparable. In osteoporosis patients aged 50 years or older, it has been reported that a history of falls predicts an increased risk of fracture within the next 12 months (odds ratio, OR = 6.67, p < 0.0001) and 24 months (OR = 4.43, p < 0.0001) [42]. A Canadian multicenter osteoporosis study showed that the number of falls in the past 12 months was an independent predictor of 2-year low-trauma nonvertebral fractures (≥2 falls: hazard ratio, HR = 1.9, p = 0.001; 1 falls: HR = 1.5, p = 0.014) among women with osteoporosis aged 65 years or older [43]. Therefore, a larger sample and longer follow-up time are needed for future studies to observe the potential efficacy of Jintiange on fall and fracture risks.

Several studies have shown that muscle strength, appendicular skeletal muscle mass, leg press strength, and short physical performance battery score are significantly positive correlated with BMD at the TH or the FN among those with sarcopenia and older adults [44–47]. However, the bivariate analysis of our study indicated only weak correlations between BMD and some of the TUG/CRT/TGT markers in the two groups. The disparities from previous studies may be due to the differences in the markers used to evaluate muscle strength (e.g., the TUG/CRT/TGT used in the present study are alternative indicators), characteristics of subjects, interventions, duration, etc. Age and sex have been reported to be two vital determinants of muscle strength [48]. Similar to previous studies, we also found age to be significantly associated with most of the TUG/CRT/TGT results in both groups. As expected, fracture history was correlated with the TUG time at week 52 in the Jintiange group, which indicates that fracture history is still an influential factor in muscle strength and balance even after intervention. Similar results have been reported in women with osteoporosis and a history of vertebral fracture, among whom multicomponent resistance and balance exercise can improve muscle strength and balance to some extent, but not the TUG test [49]. Interestingly, the number of correct steps in the TGT were significantly related to new falls in the Jintiange group both at baseline and week 52, suggesting that Jintiange might decrease new falls at least partially by improving the balance of the lower extremities reflected by the TGT. Larger, longer prospective studies with more comprehensive markers to evaluate muscle strength and balance are needed to determine the factors influencing Jintiange efficacy.

There are limitations in this study. First, this study did not measure or analyze body composition, particularly muscle mass and the muscle-to-body weight ratio, which play an important role in muscle strength and balance. In addition, the muscle strength of the core body area was not evaluated. Second, a high fall risk may indicate a high fracture risk; however, fall risk is not equal to fracture risk, and because of the short follow-up time and the limited sample size of this study, cases of new fractures in the two groups are too few to calculate the hazard ratio. Thus, determining whether artificial tiger bone powder combined with alfacalcidol therapy reduces the incidence of new fractures and falls requires further study. Finally, both groups received alfacalcidol, so the effect of Jintiange could not be observed independently.

In conclusion, compared with the combined calcium carbonate and alfacalcidol treatment, the combined artificial tiger bone powder and alfacalcidol therapy effectively ameliorates the balance and muscle strength of the lower extremities and reduces the fall risk in patients with primary osteoporosis/osteopenia. Combined with previous clinical studies of BMD improvement by Jintiange alone or combined with other drugs, it is inferred that Jintiange may have broader benefits for patients with low bone mass. Prospective studies with longer follow-up and larger samples are needed in the future.

Author contributions

All authors made substantial contributions. Authorship was listed as follow: Conception and design of the study: WB Xia. Acquisition of data: O Wang, ZF Cheng, PJ Xia, L Wang, J Shen, XJ Kong, YH Zeng, AJ Chao, LM Yan, H Lin, HB Sun, Q Cheng, M Zhu, ZM Hu, ZL Zhang, H Tang, WB Xia. Analysis and/or interpretation of data: HT Liang, O Wang. Drafting the manuscript: HT Liang, O Wang. Revising the manuscript critically for important intellectual content: O Wang, WB Xia. Approval of the version of the manuscript to be published (the names of all authors listed as follow): HT Liang, O Wang, ZF Cheng, PJ Xia, L Wang, J Shen, XJ Kong, YH Zeng, AJ Chao, LM Yan, H Lin, HB Sun, Q Cheng, M Zhu, ZM Hu, ZL Zhang, H Tang, WB Xia.

Funding

This study was supported by the National Natural Science Foundation of China (No.81900811), and the Chinese Academy of Medical Sciences-CAMS Innovation Fund for Medical Sciences (CIFMS-2021–12M-1–002).

Data availability

The raw datasets generated and/or analyzed during this study are not publicly available but are available from the corresponding author on reasonable request.

Ethics approval

The trial was performed with the approval of Peking Union Medical Hospital Ethics Committee (HS-1047).
Consent to participate
All of the subjects agreed to participate in this study and signed informed consent forms.

Registration number
The registration number of this study is ChiCTR-IPR-16008533.

Declaration of competing interest
The authors declare no competing interest.

Acknowledgement
We greatly appreciate all participants in this clinical trial. Special thanks to the generous support from GINWA ENTERPRISE (GROUP) INC. Xi’an Ginwa pharmaceutical Factory.

Appendix A. Supplementary data
Supplementary data to this article can be found online at https://doi.org/10.1016/j.jot.2022.05.002.

References
[1] Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993;94(6):646–50. Jun.
[2] Edwards MH, Dennison EM, Albie Sayer A, Fielding R, Cooper C. Osteoporosis and sarcopenia in older age. Bone 2015;80:126–30. Nov.
[3] Wang L, Yu W, Yin X, Cui L, Tang S, Jiang N, et al. Prevalence of osteoporosis and fracture in China: the China osteoporosis prevalence study. JAMA Netw Open 2021; 4(8):e212116. Aug 2.
[4] Hernlund E, Svarlander A, Igglesdorff J, Cooper C, Stenmark J, et al. The effects of vitamin D on skeletal muscle strength, mass, and muscle power: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle 2019;10(3):485–500. Jun.
[5] Teng Z, Zhu Y, Teng Y, Long Q, Hao Q, Xu Y, et al. The analysis of osteocalcin as a risk factor for J Eutresis, mortality, and falls. Osteoporos Int.; J Eutresis Coop betw Eur Found Osteopor Ostif Natl Ostif Found USA 2021;32(11):2173–83. Apr 20.
[6] Beaudart C, Buckinx F, Babenda G, Gilian S, Cavalier E, Slomian J, et al. The effects of vitamin D on skeletal muscle strength, mass, and muscle power: a systematic review and meta-analysis of randomized controlled trials. J Clin Endocrinol Metab 2014;99(11):4336–45, Nov.
[7] Remelli F, Vitali A, Zurdo A, Volpato S. Vitamin D deficiency and sarcopenia in older persons. Nutrients 2019;11(12). Nov 21.
[8] Teng Z, Zhu Y, Teng Y, Long Q, Hao Q, Xu Y, et al. The analysis of osteocalcin as a risk factor for J Eutresis, mortality, and falls. Osteoporos Int.; J Eutresis Coop betw Eur Found Osteopor Ostif Natl Ostif Found USA 2021;32(11):2173–83. Apr 20.
[9] Beaudart C, Buckinx F, Babenda G, Gilian S, Cavalier E, Slomian J, et al. The effects of vitamin D on skeletal muscle strength, mass, and muscle power: a systematic review and meta-analysis of randomized controlled trials. J Clin Endocrinol Metab 2014;99(11):4336–45, Nov.
[10] Remelli F, Vitali A, Zurdo A, Volpato S. Vitamin D deficiency and sarcopenia in older persons. Nutrients 2019;11(12). Nov 21.
[11] Teng Z, Zhu Y, Teng Y, Long Q, Hao Q, Xu Y, et al. The analysis of osteocalcin as a risk factor for J Eutresis, mortality, and falls. Osteoporos Int.; J Eutresis Coop betw Eur Found Osteopor Ostif Natl Ostif Found USA 2021;32(11):2173–83. Apr 20.
[12] Beaudart C, Buckinx F, Babenda G, Gilian S, Cavalier E, Slomian J, et al. The effects of vitamin D on skeletal muscle strength, mass, and muscle power: a systematic review and meta-analysis of randomized controlled trials. J Clin Endocrinol Metab 2014;99(11):4336–45, Nov.
[13] Remelli F, Vitali A, Zurdo A, Volpato S. Vitamin D deficiency and sarcopenia in older persons. Nutrients 2019;11(12). Nov 21.
[14] Teng Z, Zhu Y, Teng Y, Long Q, Hao Q, Xu Y, et al. The analysis of osteocalcin as a risk factor for J Eutresis, mortality, and falls. Osteoporos Int.; J Eutresis Coop betw Eur Found Osteopor Ostif Natl Ostif Found USA 2021;32(11):2173–83. Apr 20.
[41] Karinkanta S, Piirtola M, Sievanen H, Uusi-Rasi K, Kannus P. Physical therapy approaches to reduce fall and fracture risk among older adults. Nat Rev Endocrinol 2010;6(7):396–407. Jul.
[42] Bonafe M, Shi N, Barron R, Li X, Crittenden DB, Chandler D. Predicting imminent risk for fracture in patients aged 50 or older with osteoporosis using US claims data. Arch Osteopor 2016;11(1):26. Dec.
[43] Adachi JD, Berger C, Barron R, Weycker D, Anastassiades TP, Davison KS, et al. Predictors of imminent non-vertebral fracture in elderly women with osteoporosis, low bone mass, or a history of fracture, based on data from the population-based Canadian Multicentre Osteoporosis Study (CaMos). Arch Osteopor 2019;14(1):53. May 16.
[44] Singh H, Kim D, Bemben MG, Bemben DA. Relationship between muscle performance and DXA-derived bone parameters in community-dwelling older adults. J Musculoskelet Neuronal Interact 2017;17(2):50–8. Jun 1.
[45] Qi H, Shen Y, Chen S, Wang S, Zhang A, Cai J, et al. Bone mineral density and trabecular bone score in Chinese subjects with sarcopenia. Aging Clin Exp Res 2019; 31(11):1549-56. Nov.
[46] Mastavičius A, Kilaite J, Petrovičius D, Tamulaitienė M, Alekna V. Associations between physical function, bone density, muscle mass and muscle morphology in older men with sarcopenia: a pilot study. Medicina (Kaunas, Lithuania) 2021;57(2). Feb 9.
[47] Saddik H, Pintil A, Antoun A, Al Rassy N, El Hage Z, Berro AJ, et al. Limb muscular strength and bone mineral density in elderly subjects with low skeletal muscle mass index. J Clin Densitom : Off J Int Soc Clin Densitom 2021;24(4):538-47. Oct-Dec.
[48] Wu R, Delahunt E, Dittrullo M, Lowery M, De Vito G. Effects of age and sex on neuromuscular-mechanical determinants of muscle strength. Age (Dordrecht, Netherlands) 2016;38(3):57. Jun.
[49] Stanghellie B, Bentzen H, Giangregorio L, Pripp AH, Skelton DA, Bergland A. Effects of a resistance and balance exercise programme on physical fitness, health-related quality of life and fear of falling in older women with osteoporosis and vertebral fracture: a randomized controlled trial. Osteoporos Int : J Establ Resul Cooper betw Eur Found Osteopor Nfd Osteopor Found USA 2020 Jun;31(6):1069-78.